This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

GioTag: a real-world study of afatinib followed by osimertinib

Retrospective Study of Sequential Therapy with Afatinib Followed by Osimertinib in EGFR Mutation-Positive NSCLC

A non-interventional chart review based on existing medical records of patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) who were treated with first-line afatinib*, developed the T790M mutation and were then treated with second-line osimertinib.

Trial NCT03370770


EGFR mutation-positive advanced NSCLC

Common EGFR mutations (del19, L858R) at start of first-line treatment with afatinib

Initiation of second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry

Target N=190

Afatinib followed by osimertinib in patients who acquired the T790M mutation


Primary outcome measure:

  • Time on afatinib and osimertinib treatment


Secondary outcome measure:

  • To collect data on the acquired resistance mechanism to osimertinib

Trial Status

Enrolment complete


1 (Accessed: May 2018).

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.


© 2018 Boehringer Ingelheim International GmbH. All rights reserved.


Last updated: June 2018